Method of Producing Novel Unmarked Recombinant Vaccine Vector for Tuberculosis
Unusually high expression of recombinant protein Unmarked recombinant vaccine vector overcomes regulatory issues surrounding antibiotic resistance markers High stability
Treatment and prevention of M. tuberculosis for humans and M. bovis for animals Method for producing a vaccine against leprosy and other mycobacterial diseases
Investigators at UCLA have identified a method of producing unmarked, live recombinant vaccine vectors that provide high expression of recombinant proteins from genes stably integrated into the chromosome.
Patent Number: WO2013010018A3
Application Number: WO2012US46529A
Inventor: GERWICH, William, H. | PEREIRA-BADILLA, Alban, R. | BYRUM, Tara | VALERIOTE, Frederick, A. | GILSON, Michael, Kenneth | FENLEY, Andrew | KALE, Andrew | DEBONSI, Hosana, M. | MOORE, Bradley
Priority Date: 13 Jul 2011
Priority Number: WO2013010018A3
Application Date: 12 Jul 2012
Publication Date: 10 May 2013
IPC Current: A61K0031175 | A61K0031155 | A61K003116 | A61P003112 | A61P003500
Assignee Applicant: The Regents of the University of California
Title: COMPOSITIONS AND METHODS FOR INHIBITING PROTEASES | COMPOSITIONS ET PROCÉDÉS POUR L'INHIBITION DES PROTÉASES
Usefulness: COMPOSITIONS AND METHODS FOR INHIBITING PROTEASES | COMPOSITIONS ET PROCÉDÉS POUR L'INHIBITION DES PROTÉASES
Summary: (C1) is useful: for treating, preventing, partially reversing or reversing and/or ameliorating a condition, disease or infection (in human or mammal) comprising retroviral infection, HIV-1 infection, an immune disorder or an autoimmune disorder, a cancer, a myeloma or a multiple myeloma, an adenocarcinoma, a lung adenocarcinoma, a pancreatic cancer, a B-cell related cancer, lymphoma or a non-Hodgkin's lymphoma; in nanoparticles, nanolipoparticles, vesicles or liposomal membranes; for accumulating polyubiquitinated proteins in the cell, thus causing cell cycle arrest, inducing apoptosis and/or inhibiting growth or viability of a tumor cell or a cancer cell or an infected cell (all claimed); and for treating neurodegenerative disease, amyotrophic lateral sclerosis, Lou Gehrig's disease, Parkinson disease, Huntington's disease or Alzheimer's disease.
Novelty: Composition used e.g. to treat e.g. cancer, comprises e.g. 2-amino acetamido compounds or hexanoic acid ((S)-1-((S)-3-methane sulfinyl-1-((S)-3-methyl-1-((R)-2-methyl-oxiranecarbonyl)-butylcarbamoyl)-propylcarbamoyl)-2-methyl-propyl)-amide
诊断/治疗
人类免疫缺陷病毒
8932846
State of Development The vaccine has been tested on animals. Background Mycobacterium tuberculosis is a disease that infects millions of people each year; in addition, the related bacterium, Mycobacterium bovis, infects domesticated animals, resulting in substantial economic losses. Currently, humans are administered Bacille Calmette-Guerin (BCG) vaccine to prevent tuberculosis. However, BCG vaccines have variable efficacy - on average about 50%. Recombinant BCG vaccines have been developed that express a key antigen of M. tuberculosis and are more potent than BCG. However, these recombinant BCG vaccines contain antibiotic resistance markers; regulatory authorities want vaccines to be free of such antibiotic resistance markers to diminish their dissemination to other pathogens in the environment. Unmarked vaccine vectors (i.e. those lacking an antibiotic resistance marker) have been produced by various means, but these methods have resulted in low levels of expression of recombinant proteins. Preferably, unmarked strains would not only express large amounts of the recombinant proteins, but express them from genes integrated into the chromosome because such constructs tend to be more stable than when the genes are expressed from a plasmid. Due to safety, potency, regulatory, and stability issues, there is a need for a better vaccine that can prevent and treat tuberculosis in humans and animals. Related Materials Additional Technologies by these Inventors Tech ID/UC Case 20237/2007-715-0 Related Cases 2007-715-0
美国
